NEO - Earnings call transcript Q1 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to NeoGenomics' First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Doug VanOort, Chairman and CEO for NeoGenomics. Thank you, Mr. VanOort.

begin. may You

Doug VanOort

Good to Bob. I'd to like Thank quarter morning XXXX everyone first conference welcome you, everyone. call.

Vice Financial and NeoGenomics Joining Officer; Director me Sharon our of joined Virag. Kathryn Services Vice Accounting Division; Vice is headquarters Development Corporate Bill Shovlin, Steve External President Relations. Chief our of as Jones, Clinical from our Principal of Virag President our Fort our of Jessica Myers and Officer; Bonello, King, President Rob Treasurer, Reporting; President; Executive Investor Sharon McKenzie, recently Finance and

we will statements. our language Before begin the forward-looking prepared remarks, Bonello about read Bill standard

Bill Bonello

these update on materialize conference more could call one not statements call historical expectations performance, uncertainties, current our involve that facts This our of operations, which These and or statements. incorrect, those risks are nature to contain no certain made today, may materially outcomes speaks and beyond and as statements. forward-looking today. only events financial or assumptions after statements their to underlying condition we statement which indicated risks of circumstances opportunities. statements are this represents beliefs prove control. from Any substantial growth by about Should statements, obligation are and should differ and the results the any of forward-looking such forward-looking forward-looking actual or of in statements reflect undertake certainties or our Any

completed. Investor copy of that morning's our website this turning Relations will Before transcript Doug, to a the call after want the our available everyone it back of section on is shortly call we let I be making to know for

number to for to to know are questions going allotted of per chance within in a one give more this let that We person has ask call. also that been limit to to everyone order questions the hour want people two we a

Doug VanOort

Thank you, Bill.

turn and the one review, that near-term on long-term for investments Sharon both financial drive call are the of briefly some a to a I For few review over of more After then commentary will highlights, provide today's call results. financial initiatives making we of growth. detailed that to growth and will quarter review I financial and the the XXXX our additional

with begin quarter Total revenue was the quarter NeoGenomics highlights. Let's performance first XX%. one financial grew excellent.

divested Excluding the which grew test contribution volume Services approximately revenue nearly and grew from Clinical revenue PathLogic XX% summer, we year-over-year. increased last XX% X%. division

Services divisions We strong a Excluding PathLogic, and more than are clinical both nearly XX%. revenue up exceptionally market believe with Pharma that share gaining XX%. division revenue up remained grew market. in XX% growth backlog growing

we more business. in financial is lower Officer, financial pleased are and Financial At I'll call were above EBITDA once of in Clinical of flow was of collections, growth one to quarter XX.X%. well is increased and was which time We Virag see at results. increased of to review XX%. Cash Importantly, with adjusted operations the changes. in outstanding sales our Chief continued than profitably. The year-over-year Pharma were Sharon XX% both margin and since margin guidance grow to days our million, momentum the $XX record XXXX, particularly detailed over excellent record we strong. pleased our services again the a on to to quarter this challenges than level a first and cash position XXX long-term basis turn was performance my to any high-end XX% more XX%, EBITDA regulatory of point, caused financial increased EBITDA from spite by revenue points Adjusted adjusted able for all, our All

Sharon Virag

Doug. you, Thank

remind X, I Before XXXX. ASC I'd to that affective XXX January everyone begin, like adopted we

periods. years, price timing concession of not changes and revenue shown expense, adoption of had recorded also business, adoption bad changes XXX as adjusted of reduction debt, is revenue. in impact restated is recognition adopting ASC as year-over-year There The an of are reflect on some the accounted implicit of effect XXX for Hence, comparison and which profit although to lowering that also methodology, G&A now adoption a ASC the had adoption SG&A for that of XXX ASC both prior relative XXXX. The material. the revenue, have include for discussed we XXX, these EBITDA we to gross results not both of of primary Services XXX is to in the will however are part accounting of Pharma the material. for effect the all As the expense, the XXXX previously the been to

XX% first genetic testing from revenue increased revenue million. revenues PathLogic, by a were to the million, XX% Our of million and revenue After Clinical increase year year. Services adjusting sale $X.X grew XX% last for quarter $XX.X to over increased nearly total year. Pharma $XX XX%

XX% testing increased clinical year-over-year. mentioned, Doug volume As genetic

on believe to quarter from as loss XXX million growth common in in of Services a operations was clinical XXX exclude modalities to periods, versus and revenue items primarily income growth. a net that compare testing. this decrease Gross in per more growth test both expenses net loss or to available shareholders X% by by margin non-cash X%, across basis $X.X $X.XX it in of million attributable loss revenue GAAP XX% or measure the as GAAP as Importantly, more share was a sales genetic a consistent $X.XX double-digit and of prior one-time adjusted improved Pharma per was loss Average share first Company our adjust a and in test prior primarily to is from gross related the XX% $X.X was net on share. across improvement We a year contribution from points point This and XXXX, million, to $X.X year. flow the due Operating XX%. reimbursement common and, a prior net in order the loss driven FISH, This with clinical prior increase the our and year. and income growth quarter a than on well $X.X income basis cost $X than to to appropriate per of this of We increased cytometry was to certain shareholders adjusted by compared applicable, over balanced earnings in increased changes to represents if Medicare diluted investments per net million profit in net molecular more $XXX, costs. year. basis first of This regulation. a increase and income X% refer margin decline the to to reduction up per million, to by $XX.X results basis, million from the Gross XX%, year. the the marketing true diluted year

quarter, first million $X.X are million, net diluted with EBITDA million per $X year. was compared in XXXX. these In income release. was to share prior $X.XX quarter first Adjusted of We have in $X.X $X.X table earnings compared included our one, an EPS the in per the or adjusted $X.XX XX%, share calculated versus a was Adjusted million, increase how to XXXX's quarter.

the quarter positive days operations the $XX to quarter deductables. first is $XX.X patient year's from million as performance quarter in due drove flow in days year's with one Doug of one quite million cash in in in As quarter the $X.X from quarter. in strong XX sequentially especially last levels cash tends four. a were increase cash quarter ended challenging in We collections a million DSO negative improvement to quarter. of This this from mentioned, on high cash quarter to million books. notable decreased The XX first be to $XX.X collections

of contract million increases finished as personnel we the in new $XXX revolver were and with quarterly December first XXXX. at of addition liquidity, to during $XX volumes, including with borrowing the XX, testing complexities the deal QX adjust X,XXX laboratory to quarter, XX, Nearly million. March the regulations. caused total X,XXX all capacity term to our our our equivalent billing principal Our versus and the loan. temps, employees, $X.X personnel doctors, payment the of the and XXXX, total on quarter revolver, X,XXX We of debt repaid increased at full-time to by the on end At was on normal was as quarter, end

our maintaining guidance year for Adjusted are revenue full We and EBITDA.

million We million. continue $XXX to of be to expect the in $XXX range Revenue to

We continue the million. to to expect be range in EBITDA to million Adjusted of $XX $XX

four cytogenetics and impact potential Draft quarter call, flow we cuts our prior remain National Determination, well patients, discussed generation authorization. the as as for guidance or sequencing for XX-Day headwinds the changes molecular, NCD, from On seen we Based these cancer have the advanced Coverage that number comfortable Medicare to-date, to IHC, reimbursement captures to and adequately rates changes. of Medicare including on any the Rule, trends cytometry, we for next a

more guidance, our to I of some growth Doug summary Our press non-GAAP our Adjusted commentary to a and will includes measures release a this comprehensive XXXX turn over XXXX of provide to including now ranges call GAAP. EPS reconciliation and back the additional EPS on morning initiatives.

Doug VanOort

Sharon. you, Thank

update question begin XXXX long-term and and call, provide to both are we we on and Before growth. I some the segment initiatives the growth our making of answer that of investments drive like to would an near-term this

near-term for outlook remains growth Our positive.

payers adding is accounts, several organization and strengthen types contracts. position hospital new care we new quarter arrangements and of by with pipeline helped of to These purchasing add to and the very hospital healthy. us groups a the During of continued our competitive important group managed number accounts

we retention. very the for meet are services, we client service Importantly, levels increasing our continue To exceptionally and capacity. our adding levels are be Division high Clinical strong of to maintaining demand

small cytometry turnaround clients month Georgia deliver we for Atlanta area. will Lab flow to in to program delivering next We faster to disclosed, have allow an the us rapid outstanding a time previously clients. provide the This extremely turnaround clients rapid even marketplace. consistent to and already Atlanta new As Lab flow within in large cytometry that opening service services in are

menu. comprehensive contracts We is In during for continue being test enhanced services throughout we quarter America, number We our our of in most since clients of one ended Pharma test one-stop-shop country. nine and approximately million The and team important the of Services, comprehensive work. new provides future an or the Pharma the $XX $XX in year. robust. with net our remains booked tests menu by for introduced beginning We pursued this contracts quarter believe we signed contracts million very new invest to new oncology oncology of the

We significantly Services. capabilities are adding upgrading capacity and our in Pharma

new staffed, just and in begun Rolle, to has lab instruments validated, process are specimens. Switzerland Our is

end. level to volume at expect up by year break-even be and We project a ramp

good, next for are foot serve other This capabilities Texas. will us prospects our will to We nearing Houston flow and of regional This generation Lab Texas. our in both and Services growth science molecular growth clients also and rapid square markets the growing demographic accelerate also immunohistochemistry. Clinical also medicine. for expanded and sequencing to primarily changes and XX,XXX for cytometry, significantly in long-term testing, testing division Laboratory can oncology completion division We to facility and due are Services Pharma as a new are serve our advances in believe purpose-built with help

of testing the one some NeoGenomics test than XX,XXX in XX% As one to grew in leading over long for we molecular investment particular, as is Molecular testing, is a put like In business. result, more molecular already tests. the providers about the to our world in In details our testing of of order this are cancers area I term. somatic NeoGenomics an investment of oncology quarter existing year-over-year companies focus. would one, than position in more molecular investing volume to perspective, to U.S. the the largest share

we provided year. increase from than quarter, more of prior multi-gene an the During panels, the more X,XXX than XX%

facilities. pharma are for advanced believe tests most our run million. molecular panels molecular have offerings different to that one that of Burden all in testing sequencing, the U.S. XXX approximately profiles Real including; multi-gene to capabilities larger tests, major Tumor We molecular provide tumor offer XXX Mutational fragment CAP-accredited, for we length NeoTYPE currently for utilize among as of Our and country, testing customers rate tests Cancer offer testing in genes. microarray. technologies called molecular XX test the new as largest XXXX and revenue many $XX therapies. and We Sanger information We We Time-PCR, panels covering single to the next-generation sequencing, customers clinical is cancer and mutations the molecular and analysis, testing our CLIA-approved the over immunoncology gene Profiles, offer We in

and technologies. Our system, Next use pharma nCounter instrumentation, have a NanoString's laboratories to the work our even Ion new customers of available test including and to develop significant Pharma clients. MiSeq, us Torrent Fisher's commercial and to Generation opportunity with customers host Sequencing requirements, platforms existing From perspective, tests. more customize other tests Thermo a also system to customize Services have to or their clinical HiSeq Illumina's NextSeq ability is

prediction clinical significant of tests diagnosis, business. aspect the ongoing molecular prognosis, every I'd to that genetic predisposition. two describe of cover With detection Our our in to response molecular testing including therapy, of and investments of background, oncology like

continuing investments We support are our to and develop make multi-gene to panels.

believe we clients covered. they as provide on discussed them, these a the the they coverage will third-party in sporadic expect We currently we've want eventually because past, we sometime improve medicine, will future. panels, these differentiate of good us is be money from and best. However, tests our these Frankly, competition, the for help that are reimbursement in at reimbursement number they we panels lose but that

our this test. next approval the of our seek large from to sequencing initiatives is generation FDA regard PMA in for single-site One multi-gene

We the of Obviously, filing this product invest are our in pre-submission currently development. important process letter. this to is are involved, we in and committed quite process

question to in researchers area business, cure and future. we Bill period. us making important to lead prevent, for reimbursement oncology is in and their the search position molecular competitively as our for are many testing lead improved today, Molecular through and in the this a each to in over initiative will testing physicans call answer expect I'll and years come. to hand commit a vitally We to testing to treat a to We cancer. Bill? NeoGenomics of in now tool Bonello leader investments lead and

Bill Bonello

At up we'd to open for this like point, it questions.

we'll like already subject via If the webcast if call us a you and listeners. and matter your are to only addressed listening at hasn't address Q&A feel session the would email question, the to during by at call-in questions conference bill.bonello@neogenomics.com please free submit this been to our end

everyone call, we to allotted Operator, the for ask now this person we at from each so mentioned call this still within two, to keep and beginning that questions open questions. for hour As may limit up their you the of would the hear like call. to may

Operator

Murphy first comes with Please question the Blair. question. Thank your Our you. [Operator Instructions] William Amanda proceed from line of with

Amanda Murphy

Hi. Doug have quick Good around you follow-ups some just made few morning. the sequencing on panel. I a comments that

with first, guess I So FDA.

you yet. they the covered PMA a And should you're don't be entities? don't for So sense, under to claim, the have or got intention talk for looking the they indications clearance then is the seek I which any I about CDx new CDx know done panel, that you at potentially how with think so using are can process if chance to FDA

Doug VanOort

to question, companion FDA. submit Thanks existing Amanda. for include plan for large would which by the the panel, approved the FDA companion to Yes, testing diagnostic test diagnostic a we

Amanda Murphy

broader question Okay. And panel. then sort I of just, got a sequencing on I guess, this

terms to make their market? of you this single the there take panels of I sort think and of for Thanks. that kind of multi-gene. a you methodology how there? And maybe from were labs well change particularly we look model, your and try in able so how wise, think platform also investors many I market do to to are – if FDA question positioned distributed that what maybe time kind just the providers complexity sure through trying am anywhere guess and the wise them, some walk the just between and as data think products over your the could more of is in and – obviously you definitely you're there is But get gene through could of

Doug VanOort

panels multi-gene the about as implications. target broken talked mutations So we these a and in been type We lot are that tumor have you we into which down hospitals these of a panels to because they therapeutic popular as sold extremely goes past. driver typically have of have billing know, lot our genes

said even – are panels going they to in popular, and remarks, expect XX% It's very done these do We here panels. very the one. I have in changing spectacular. rapidly. Science in sales is quarter been has in growth been be mentioned that our those these so, I And prepared as changes about

in alternatives how rapidly. trials therapeutic Our changing mutations these affect is relative and and of combination to physicians understanding clinical very in possibilities individually

So, also two will to these are over long-term. PMA we a we for the be think help to panel the weeks FDA within will to but popular, us looking pre-submission which panels which very to letter think next through we continue that we the probably competitive FDA a are a larger be larger panel it at process send the going

Operator

you. Thank

of proceed line Please next question question. your comes from the Ellich Craig-Hallum. Kevin Our with with

Kevin Ellich

for more us out guess performance with growth, booked really Doug, question. contracts. we of can I driving a clearly that what's with Good months? backlog. as the nice little to give million you color the I and the there over nice How next the start bit see it Thanks to on and taking XX through just flow should morning. the wanted improvement pharma $X

Doug VanOort

Yeah. Kevin, in advantages we good think we pharma. competitive have some

Some our called molecular also we that that this clinical of proprietary FISH for in business have pharma, testing, cytometry, advantages we MultiOmyx pharma semi also in competitive provide and immunohistochemistry clients. the technology flow exist given

in in and MultiOmyx, So four signed contracts we modalities them. of of we that each a each very have number of gaining a that molecular are we have believe growth actually are those four And we business the potential testing. good

because even projects. X contracts the technology Phase X in are believe in our number a have cytometry the that bit backlog of getting we've the to in and I marketplace contracts Switzerland duration, type flow penetrate are Phase that a new added we some longer are U.S. that both now We with starting in and of little

over bit longer than realized bit going the little to are know, backlog to increased of So, of quickly year-over-year has But, realize grow, revenue quarters, we past. revenue little has these last been as a continue. two expect period that in our has quite the into we you started for we've and expect strong that our a revenue the we've had be more to some revenue started time as and growth

Kevin Ellich

you'd changes general from to kind from of broader us statements impact any reimbursement what seen kind you've Then the Rule, or wanted sequencing? impact some see just PAMA next-gen XX-Day if of give

Doug VanOort

few that let comments Yeah, a well. take to have may and as me try Sharon

has PAMA all year. us impact of First a this not in been significant for

most using the is the you As physician testing rather schedule paid that schedule impacts and PAMA fee fee fee our clinical for of schedule. than clinical know lab the

in Sharon cytogenetics think of are reimbursement per that. who further I So molecular impacts affected Clinical testing and do number changing mentioned prepared and on PAMA. remarks of other by have Rob Shovlin in her We has test is President division our are I that think that comments our a some

RobShovlin

again. Hey Kevin, Good to it's you with Rob. talk

the on the effect on on performed to just January the setting. in lab XX-days setting. reference XX-days reference X, Rule, must procurement laboratory molecular that January of now the sample a a are pathology non-hospital place XX-Day for test any sample within non-hospital Rule But a outpatient under procurement for took test XX-Day as labs within So, performed rule prior hospital of prohibited hospital Medicare new which in certain Medicare from fill X, reminder, XXXX, billing

of guidance, we with many cases, molecular that lower have clients exchanges. really than here impact historically captures adequately form the and test pertains comments, Sharon Medicare. been on rates to-date the clients. So, in gave most hospital seen to the now, In trends Medicare our slightly but potential what our billing rates, billing to we've that comfortable our hospital remain billed we any And are from directly to go our based

Operator

you. Thank

with of question with Drew Jones line next proceed Please the comes Stephens, Our your Inc. question. from

Drew Jones

the that the for was FDA in The XXXX? telegraphed panels, you that pathway spend got million in for $X spend molecular contemplated growth

Doug VanOort

Yes Drew, it was.

Drew Jones

the And maybe spend, and a from us quarter the incremental sustainable seasonally growth incremental and level incremental point? quarter, of then on the revenue EBITDA that XX% update in is this as deployment margin, of weak on far at the that the margin margins

Doug VanOort

we think EBITDA the adjusted good that expect on I I XX% better to, guidance to able going we're incremental drive for think to which And gave which to programs, cost thing, for were is to We XX% stick scale adjusted allow we EBITDA, says of automation, a drive but EBITDA us. growth. than the programs, side revenue Here cost incremental reduction should that's that think what advantages, containment good of first The high quarter. we expect programs, I forward. probably continued sort on that cost going to XX% the us benchmark

Operator

Thank you.

next Paul Please line comes Janney of Scott. from question. Montgomery Our with your Knight proceed question the with

Paul Knight

million was What the growth mentioned rate run or the a was had you on molecular year-over-year? that rate Doug, year $XX ago tests. what

Doug VanOort

actually don't to question. know I the that Paul, answer

Paul Knight

Okay.

Doug VanOort

think… Bill do I you,

Bill Bonello

of to I Yeah, the data, disclosed a not that of on more to think are on – provide molecular the in by molecular We quarter. it's sense the have Paul we we give numbers going of kind we're space, but we our the this what did but you information volume some not player grew we're necessarily routine that than say XX% basis. a in call

Paul Knight

it. then Is a price the pricing question next Got average it's question, the quite Historically And my than. X% second been down Okay. new – quarter. normal? more this bit in my

Sharon Virag

sure, that mean that reimbursement the more work the for and mix revenue through, I'm per I'm the the seen. I we've payer some believe we So, X% then around think as not is We of the decline cuts new was historical. I normal? Medicare test

consider I that we're would new the be So, else continuing normal. down. know add But that? if I those, to to would but want Anybody through it to don't work

Doug VanOort

Okay.

Bill Bonello

We our test average we that we've delivered to guidance per $XXX revenue be to $XXX the for stick year. that previous by expect

Operator

Thank you.

proceed Please your of comes Our The Myers from question. with Company. line next question with the Raymond Benchmark

Raymond Myers

is FDA that this seeking? clearance that of morning. question and pre-submission panel are the Good large you first are new what letter discussed, you milestones Doug, for the you. beyond Thank timing

Doug VanOort

Thanks Ray. question, for your

been a that process. think a there As lot you through There I been FDA gone haven't have of couple know, these. the – have has

these helping year. have some to kinds And us as is of this of and around processes be think helping frame There working that would benchmark a sort for consultants kind on teams has and are take that that us. indicated that works time work should be us. a well. we And of the a of are lot So, done, we – that we we're have FDA for they

Raymond Myers

the of be would something? actual And the milestone, submission next Great.

Doug VanOort

pre-submission Yes, the that EMA letter be submission. going this and there meeting is process which is single And there is very a have to made soon we'll would site with FDA we undertake. is and a then whole

Raymond Myers

Okay great. And then second question is receivables around – QX for strong Sharon actually. Sharon, collection? what supported the very

Sharon Virag

The a that on that for QX add. we the to that our of the education Making that of receivables all collection were different XX-Day the was necessary think certainly kind as at the all everybody us to able get the making new of we kind and are beginning billing Anything gotten – I teams on And bit was that's information then, I getting handle order. think the would of of getting Rule perspective by get we've sure then of our show you sure hands our used end it. quarter, it, in quarter, getting Doug, and customers.

Doug VanOort

got billing the and And billing on much we've again reflect to we you DSO very Clarient strong as automating with really as the implement And of the under team that a that last to getting DSO the and we there. that. used integrate here and level year, know We're processes. and good we're the our lot cash prior billing of is achieved kinds acquisition. work I achieving We to at billing team, Company, we was we're system process the – collections the as think have Ray, can integrated once think good drive billing these levels system a there – management. the We strong going billing

Raymond Myers

So, thanks. excellent, congratulations,

Operator

next the our of you, with with Thank First question line Please questions. comes proceed your Munda Analysis. from Joe

Joe Munda

questions. for Doug. quick, you Thank taking Morning. Good the Real

tests will per far from are forward how able reduction per out as outpace in you've continue Are XXXX? year-over-year cost As concerned, am strip we revenue just you can I look been costs. we test? quarter-over-quarter, per over that going to much expected the as test to out strip these cost mean, more I out test curious

Doug VanOort

Joe. question, the for Thanks

lot We is have test reasons in been a to reasons platforms for existing are of some growth volume that growth those is successful in what some we And that to continue a expect for cost of time. overall cost per we on One the that. test. volume using lower are reducing our drive reason we In per scale. for our bringing

are also work we of the We automating a lot do. that

are throughout our deploying laboratories. Lean also We practices

We in advantage are also thing. using for our savings of that supplies sort and scale

revenue So, reductions we bear there to test test are period seeing cost in are expect we future foreseeable the per of bringing And the outpace that at to certainly for least test. that lot our some of we time. a that per tools are that that reduce for and continue our can think that we cost per reductions will

Joe Munda

PD-LX on impact the And tests revenue us. And quarters am average Was just an you an the quarter? being lot talked much test? overall of about talked Medicare extent get in tell was am issue, of but to the how that I past, I can a a you about in the you regards to driver? was how quarter? contributor I in PD-LX. contributor just curious the themselves, much of it to a have in the actually then wondering How know did per how reimbursement PLX some much space

Doug VanOort

PLX was pretty much annualized one. growth that quarter in was but XXXX, in a big growth driver

revenue either of per change a our quarter. significant or our cost not change test in was PD-LX there in So the per test impact

Joe Munda

Okay. And then couple of more here.

curious I how correct, am versus much just of In terms of customers? existing million was backlog this that roughly added quarter. $XX new

Doug VanOort

Joe, new breakdown the is a just that that feel but I my relatively have you lot customers. exact came from of guts that can don't I tell

of sales are number pharma tenure that in We up on – the clients. of and our sales a now new coming almost team average lot They think two they years the traction approached team is have marketplace. is a I getting of

that coming think small a good some many very of have are projects clients I them both with pharma And the number clients. new We of and from relationships I think large.

Joe Munda

Okay.

you reps So remind have just selling how pharma you us many do services? can

Doug VanOort

right and seven for to are We representative Geneva. another of just now. in hired Europe Europe just well in And as we one outside are looking we lab our there in support

Bill Bonello

This to and limit, going else, two it of stick to have To we'll you to try I there, the fair Hi, couple end like we is Bill. sneak there. but everybody question are extra Joe. we to think a be

Operator

for like comments. to questions [Operator further are you. turn Thank no at time. I'd this the to closing Instructions] back management There floor

Doug VanOort

and you everyone Bob, you, thank Thank for Okay. questions. your

want end and the like I call, us company. joining recognize our the for team time morning, building I'd On to NeoGenomics this quarter commitment that XXXX. to will second call testing team, X,XXX thank around on and around you XXXX know of cancer-genetics earnings for members July you dedication your we be their let the held or approximately behalf world-class in XX, a Before U.S. to NeoGenomics our

For those our your investors of bye. Company. you or we an in for you listening Good in that thank investment are NeoGenomics, considering interest are

Operator

teleconference. today's concludes This

disconnect time. your this may Thank line You for participations. you at your

NeoGenomics (NEO) 1 May 182018 Q1 Earnings call transcript